Catabasis Pharmaceuticals (NASDAQ:CATB) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Catabasis Pharmaceuticals (NASDAQ:CATB) announced its earnings results on Thursday. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.07, Fidelity Earnings reports.

NASDAQ:CATB traded down $0.17 on Friday, hitting $5.12. The stock had a trading volume of 69,300 shares, compared to its average volume of 126,241. Catabasis Pharmaceuticals has a 52-week low of $3.60 and a 52-week high of $9.76. The business’s 50-day simple moving average is $5.10 and its two-hundred day simple moving average is $6.52. The stock has a market cap of $61.22 million, a price-to-earnings ratio of -1.00 and a beta of 1.73.

Several brokerages have issued reports on CATB. Wedbush reissued an “outperform” rating and issued a $18.00 target price on shares of Catabasis Pharmaceuticals in a research report on Monday, July 29th. Citigroup dropped their target price on Catabasis Pharmaceuticals from $72.00 to $60.00 in a research report on Friday. Zacks Investment Research cut Catabasis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 16th. Finally, ValuEngine raised Catabasis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD).

Featured Story: How to Invest in Growth Stocks

Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)

Leave a Reply

Your email address will not be published. Required fields are marked *

*